Motor neurone disease: assessment and management (NG42)Product type:GuidanceProgramme:NICE guidelineLast updated: 23 July 2019Published: 24 February 2016
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 September 2017
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2001
The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)Product type:AdviceProgramme:Medtech innovation briefingPublished: 14 September 2018
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC